"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.

Over 32 years, the portfolio in The Oberweis Report has returned an average gain of 21.2% a year vs. 7.9% for the S&P 500. Here, money manager and newsletter advisor Jim Oberweis, Jr. looks at Suntech Power Holdings Ltd. (NYSE: STP).

"Long-term results notwithstanding, 2008 has been humbling, to say the least. No other year in our history has been as challenging.

"But in our experience, the most favorable buying opportunities tend to fall after a period in which the market has not performed well.

"Although year-by-year results can be volatile, disciplined investors who remain fully invested in a portfolio of high-growth equities selected using our methodology have historically achieved an exceptional average rate of return over long periods of time.

"Suntech Power Holdings Co., Ltd is one of the leading solar energy companies in the world as measured by production output of photovoltaic, or PV, cells, with leading positions in key solar markets such as Germany and Spain.

"While this has been an ugly period for equities, we believe an above-average risk/reward opportunity presently exists for the small-cap growth market," says Jim Oberweis, Jr., monoey manager and editor of The Oberweis Report.

He adds, "P/E valuations of our universe of high growth companies are now substantially below average. Most important, our research indicates that such periods are also opportune times to buy." Here, he offers a pair of retail ideas -- Guess? (NYSE: GES) and Lululemon athletica (NASDAQ: LULU).

"While it can be difficult to seize such an opportunity in the face of overwhelming pessimism, those who unemotionally understand the math of historical valuations should reap the rewards of seeing opportunity in the current difficulty.

"In each case, uncertainty at the time led to a large market decline that resulted in stock valuations substantially below historical averages. In virtually every period in which average P/E's for high growth stocks have dropped sharply below the mean, the economic outlook was bleak. It is exactly that pessimism and uncertainty that causes investors to relentlessly sell, creating cheap valuations.

"Get ready for a bumpy ride as the market digests tighter credit, unfavorable future economic policy, and limited options for fighting inflation," says growth stock money manager Jim Oberweis Jr. Nevertheless, he advises, "But don't get all depressed on us; valuations for U.S. companies, relative to the rest of the world, are cheaper than we have seen in awhile."

In his The Oberweis Report he sees upside potential in two high tech communications stocks that he considers suitable for risk-oriented investors: Ceragon Networks Ltd. (NASDAQ: CRNT) and Synchronoss Technologies (NASDAQ: SNCR).

Ceragon Networks Ltd. he says, is a leading provider of high-capacity wireless backhaul solutions for cellular and fixed wireless operators, enterprises and government organizations.

Despite the difficulties faced by Vonage (NYSE: VG), the future for VoIP -- Voice over Internet Protocol -- remains attractive to growth-oriented advisors. Jim Oberweis Jr. notes, "VoIP is finally gaining traction -- and people are now getting rid of their phone lines in droves, as the quality of VoIP has dramatically improved."

Indeed, the money manager and editor of The Oberweis Report notes, "At my home, we've replaced our regular phone service with a VoIP connection and I find it virtually indistinguishable from traditional land-line connections."

For those unfamiliar with the technology, he explains, "With VoIP, your voice is converted into a digital signal that travels over the internet. The price is right -- around $35 bucks a month -- for unlimited calls around the world."

Importantly, he does not see the upside opportunity among telephony service providers. Rather, he sees the potential among companies that make the equipment that enables VoIP networks to operate.

He notes, "VoIP is causing an exponential increase in demand for bandwidth." And that, he notes, takes lots of investment and equipment. It represents, he suggests, "the renaissance of the telecommunications equipment industry after six long years in the doldrums." So what companies will benefit from this renaissance?

Each year Steven Halpern, editor of TheStockAdvisors.com, surveys the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is part of his 24th annual Top Picks Report.

Tessera Technologies (NASDAQ: TSRA) is a favorite speculative idea for 2007 from Jim Oberweis, editor of The Oberweis Report. The small-cap growth advisor explains, "We screen for companies that are delivering accelerating earnings and sales growth rates -- and ideally those that are not widely followed by Wall Street.

"Tessera develops semiconductor packaging technology that allows semiconductor manufacturers to miniaturize the chip and to improve performance. The San Jose, California, company has signed license agreements with manufacturers representing 80% of the worldwide dynamic random access memory (DRAM) market, including Micron Technology and Samsung Electronics.

"DRAM in personal computers is shifting to DDR2 DRAM, which utilizes TSRA's packaging technology, and DDR2 is expected to represent roughly 75% of DRAM shipments in 2007. TSRA receives a per unit royalty for each DDR2 DRAM shipped by their licensees.

"For the quarter ended September 30, 2006, Tessera posted an 841% jump in earnings per share on a 460% rise in revenue. I believe that Wall Street's consensus estimate for revenue ($198.8MM) and earnings per share ($1.08) for 2007 are too low. Lower litigation expenses in 2007 as patent litigation subsides should drive operating margin expansion as well."